2020 The Year Of RAP, page-1105

Exactly! ResApp could play a vital role in identifying the seriously ill from this virus early and potentially save their lives as they could seek medical help in a more timely manner. It's a no brainer to get this technology out to the community as soon as possible!!

Pediatric clinical study 2016:

"The research team also performed a preliminary evaluation of the algorithms’ ability to separate bacterial and atypical pneumonia from viral pneumonia. These preliminary results demonstrated that ResApp’s algorithms could achieve accuracy of between 89% and 92% for the separation of these different types of pneumonia."

Also more groundbreaking news from the adult clinical study from December 2017:

" Demonstrated, for the first time, accurate differential diagnosis of community-acquired pneumonia and acute asthma within an adult intended use population (those experiencing
a broad range of respiratory illness) at 90-91% positive percent agreement and 88% negative percent agreement with clinical diagnosis".

The reason why the death toll is rising from the Corona virus is not from the upper tract respiratory symptoms. The unfortunate people that are passing away from this virus are the ones that develop lower tract infections that lead to pneumonia. As our company has proven in the quotes above.

"Coronavirus disease (COVID-19) is characterized by mild symptoms including a runny nose, sore throat, cough, and fever. Illness can be more severe for some people and can lead to pneumonia or breathing difficulties.
More rarely, the disease can be fatal. Older people, and people with other medical conditions (such as asthma, diabetes, or heart disease), may be more vulnerable to becoming severely ill."

Granted our technology in the US for pneumonia identification is lagging due to the unfortunate percentage outcomes from the SmartCough - C2 study for the reasons already known to the market. Now that many more people are suffering from pneumonia a retrial should be considered urgently in the U.S. to prove our technology. Visits to the ED Ward were extremely low and only made up a small percentage of the total number of test subjects presented within the study in the US. Times have changed now due to this coronavirus. A small-scale study should be urgently considered! Europe and Australia different story for pneumonia we achieved excellent results and we should push it through NOW...

Cheers

Red bar